Supernus Pharmaceuticals (SUPN) News Today $33.05 -1.54 (-4.45%) Closing price 04:00 PM EasternExtended Trading$33.03 -0.02 (-0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Supernus Pharmaceuticals, Inc.: Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant DepressionFebruary 20 at 3:25 PM | finanznachrichten.deStifel Nicolaus Remains a Hold on Supernus Pharmaceuticals (SUPN)February 20 at 3:25 PM | markets.businessinsider.comSupernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down - Should You Sell?Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Down - Here's WhyFebruary 20 at 11:53 AM | marketbeat.comCantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN)February 20 at 10:24 AM | msn.comCantor Fitzgerald Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to NeutralCantor Fitzgerald cut Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $57.00 to $36.00 in a research note on Wednesday.February 20 at 7:10 AM | marketbeat.comPeregrine Capital Management LLC Sells 63,974 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Peregrine Capital Management LLC lessened its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 32.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,678 shares of the specialty pharmaceuticFebruary 20 at 4:20 AM | marketbeat.comSupernus Pharmaceuticals Inc (SUPN) Announces Phase 2b Study Results for SPN-820February 19 at 5:08 PM | gurufocus.comSupernus plunges on trial setback for depression therapy; Cantor downgradesFebruary 19 at 3:08 PM | msn.comBREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's InvestigationFebruary 19 at 11:33 AM | globenewswire.comSupernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression TrialFebruary 19 at 10:50 AM | benzinga.comCantor downgrades Supernus on ‘disappointing’ depression studyFebruary 19 at 10:06 AM | markets.businessinsider.comSupernus plunges as mid-stage trial for depression therapy failsFebruary 19 at 10:06 AM | msn.comSupernus Pharma stock tumbles after failed depression studyFebruary 18 at 7:03 PM | in.investing.comSupernus announces SPN-820 trial misses primary endpointFebruary 18 at 7:03 PM | markets.businessinsider.comSupernus' depression treatment fails mid-stage trial, shares plungeFebruary 18 at 7:03 PM | msn.comSupernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant DepressionFebruary 18 at 4:25 PM | globenewswire.comRice Hall James & Associates LLC Trims Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Rice Hall James & Associates LLC trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 528,345 shares of the specialty pharmaceutical company's stock after selling 12,44February 18 at 6:49 AM | marketbeat.comSupernus Pharmaceuticals (SUPN) Projected to Post Earnings on TuesdaySupernus Pharmaceuticals (NASDAQ:SUPN) will be releasing earnings after the market closes on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665097)February 18 at 4:57 AM | marketbeat.com41,426 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Empowered Funds LLCEmpowered Funds LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 41,426 shares of the specialty pharmaceutical company'February 16, 2025 | marketbeat.comARMISTICE CAPITAL, LLC Reduces Stake in Supernus Pharmaceuticals IncFebruary 15, 2025 | gurufocus.comSupernus Pharmaceuticals Inc (SUPN) Announces Upcoming Financial Results ReleaseFebruary 11, 2025 | gurufocus.comSupernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsFebruary 11, 2025 | globenewswire.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Stephens Investment Management Group LLCStephens Investment Management Group LLC cut its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 9.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,752,068 shares of theFebruary 9, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Position Reduced by Trust Point Inc.Trust Point Inc. trimmed its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 47.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,521 shares of the specialty pharmaceutical company's stock afterFebruary 7, 2025 | marketbeat.comSupernus: New Approval Holds Promise Of Increased GrowthFebruary 6, 2025 | seekingalpha.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 9,477 SharesFebruary 6, 2025 | insidertrades.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $376,236.90 in StockSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.February 5, 2025 | marketbeat.comSupernus Pharmaceuticals exec sells shares worth $376,236February 5, 2025 | investing.comSupernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s DiseaseFebruary 5, 2025 | markets.businessinsider.comSupernus stock price target raised to $44 at TD CowenFebruary 5, 2025 | msn.comSupernus Pharmaceuticals, Inc.: Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's DiseaseFebruary 5, 2025 | finanznachrichten.deSupernus announces FDA approval of ONAPGOFebruary 5, 2025 | markets.businessinsider.comU.S. FDA approves Supernus' drug-device combination for Parkinson's diseaseFebruary 5, 2025 | reuters.comStifel maintains hold on Supernus, price target at $38February 5, 2025 | msn.comSupernus stock surges on FDA approvalFebruary 5, 2025 | msn.comSupernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 52-Week High - Should You Buy?Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year High - Should You Buy?February 4, 2025 | marketbeat.comSupernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's DiseaseFebruary 4, 2025 | globenewswire.comSG Americas Securities LLC Takes $391,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)SG Americas Securities LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,804 shares of the specialty pharmaceutical company's stFebruary 4, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Trading Down 5.7% - Here's WhySupernus Pharmaceuticals (NASDAQ:SUPN) Shares Down 5.7% - Should You Sell?February 3, 2025 | marketbeat.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Position Raised by China Universal Asset Management Co. Ltd.China Universal Asset Management Co. Ltd. lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 87.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,866 shares of the specialty pharmaceuticFebruary 2, 2025 | marketbeat.comSupernus Pharmaceuticals exec sells $129,676 in stockJanuary 30, 2025 | msn.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $27,734.00 in StockJanuary 30, 2025 | insidertrades.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt Sells 700 SharesSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This represents a 6.45 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 29, 2025 | marketbeat.comSupernus announces U.S. FDA approved an update for label for QelbreeJanuary 28, 2025 | markets.businessinsider.comSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Pacer Advisors Inc.Pacer Advisors Inc. reduced its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 8.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,597,456 shares of the specialty pharmaceutical company's sJanuary 28, 2025 | marketbeat.comSupernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year High - What's Next?Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 12-Month High - What's Next?January 27, 2025 | marketbeat.comFDA approves Qelbree label update for ADHD treatmentJanuary 27, 2025 | msn.comSUPN stock soars to 52-week high, hits $39.38 amid growthJanuary 27, 2025 | msn.comSupernus Pharmaceuticals Inc (SUPN) Announces FDA Approval for Updated Qelbree LabelJanuary 27, 2025 | gurufocus.comWedge Capital Management L L P NC Acquires Shares of 53,331 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)Wedge Capital Management L L P NC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 53,331 shares of the specialty pharmaceuticalJanuary 21, 2025 | marketbeat.com Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address SUPN Media Mentions By Week SUPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SUPN News Sentiment▼-0.280.60▲Average Medical News Sentiment SUPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SUPN Articles This Week▼214▲SUPN Articles Average Week Get Supernus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JAZZ News CORT News PRGO News PCRX News OMER News NKTR News ASMB News CPIX News LLY News JNJ News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SUPN) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Supernus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Supernus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
